Navigation Links
Herbal remedy used to treat hepatitis C proves ineffective, Penn study finds
Date:7/19/2012

PHILADELPHIA - Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania. Milk thistle fruit extracts have been widely used by patients in treating liver disease based on previous evidence showing that it has anti-inflammatory, anti-oxidant, and potentially anti-viral properties. However, the new study is the first rigorous trial of its kind conducted to assess true efficacy in a group of hepatitis C patients who were previously unsuccessfully treated with interferon-based therapy the standard anti-viral method used to treat the disease. Full results of the study are published in the July 18 issue of The Journal of the American Medical Association.

The Centers for Disease Control and Prevention (CDC) estimates that 3.2 million persons in the United States have chronic hepatitis C virus (HCV) infection. Of those, the study says 33 percent have reported current or past use of silymarin to treat the disease. The new study was designed to measure the potential benefit of increasing doses of silymarin in patients with chronic HCV. To determine efficacy, researchers monitored levels of serum alaninie aminotransferase (ALT) the enzyme found in the blood stream that is most often tested to identify liver disease. Low levels of ALT are normally found in the blood, but are elevated when the liver is damaged or diseased. Secondary outcomes included quality-of-life measures.

"By all indications, silymarin is no more effective at treating hepatitis C related chronic liver disease, in those who failed standard therapy with interferon, than a placebo," said K. Rajender Reddy, MD, professor of Medicine and medical director of Liver Transplantation at Penn Medicine, and senior author of the study. "This is a landmark study as millions of people around the world are looking for supplements and other forms of alternative medicines to help reduce ALT levels every year."

The trial, which included 154 adult participants with chronic HCV, was conducted over the course of two years at four medical centers in the United States. Participants were randomly assigned to receive 420mg silymarin, 700mg silymarin or a matching placebo administered three times/week for 24 weeks, a standard duration of treatment. After 24 weeks, researchers found only two participants in each treatment group achieved lowered ALT levels. Neither the average decline in ALT activity nor quality-of-life measures at the end of treatment differed significantly across the treatment groups.

"These data show that even higher-than-normal doses of silymarin don't significantly reduce ALT levels for patients with HCV," said Reddy, noting that the doses used in the trial were three and five times higher than the customary dose. "At the end of the trial we saw no significant changes in physical or mental health assessments between the patients who received treatment, and those who did not. Quality-of-life measures were also largely unchanged."


'/>"/>

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Herbal Remedy Ingredient Tied to Cancer, Kidney Failure
2. Efficacy of herbal remedies for managing insomnia
3. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
4. Clinical insight improves treatment with new lung cancer drug
5. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
6. Study Suggests Treating Dyslexia Before Kids Learn to Read
7. Rapid Asthma Treatment in ER May Prevent Admission
8. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
9. Breast cancer patients suffer treatment-related side effects long after completing care
10. Mayo Clinic offers newly approved treatment for acid reflux disease
11. Mobile Stroke Units Might Trim Time to Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology: